A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania

Key facts

Sponsor

Fidec Corporation

Principal Investigator

Vytautas Usonis, Prof

Vilnius University

Intervention

Sabin mOPV2(biological)

Enrollment

100 target

Eligibility

1-5 years · All sexes

Timeline

2015 – 2016

Collaborators

Bill and Melinda Gates Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Poliomyelitis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE4NCT07457060
  Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine
  Sinovac Biotech Co., Ltd
• RECRUITINGPHASE2NCT06895486
  Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation
  PATH
• RECRUITINGPHASE4NCT07354269
  Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations
  Sinovac Biotech Co., Ltd
• RECRUITINGPHASE1, PHASE2NCT06577298
  A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers
  CanSino Biologics Inc.
• RECRUITINGPHASE1, PHASE2NCT06137664
  Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines
  PATH
• ACTIVE NOT RECRUITINGNANCT06218368
  A Tool Kit to Improve Vaccine Confidence in the Philippines
  University of Toronto
• RECRUITINGPHASE2NCT05644184
  Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh
  PATH
• ACTIVE NOT RECRUITINGNANCT02089880
  Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis
  Shirley Ryan AbilityLab

See all trials for Poliomyelitis →